BAM15 (BAM15 (Mitochondrial Uncoupler))
A next-generation mitochondrial protonophore ("uncoupler") researched as a metabolism-boosting fat-loss agent. Unlike the dangerous older uncoupler DNP, BAM15 shows a much wider safety margin in animals, drawing strong biohacker curiosity.
How it works
Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS.
Key facts
- Molecular weight: 402.28 Da
- Half-life: Short (hours in animal models)
- Bioavailability: Oral (animal studies)
- Storage: Room temperature, protect from light (research material).
Dosing overview
- Typical dose: Not established for humans
- Frequency: Research protocols only
- Duration: Experimental
- Route: Oral (research)
Protocol notes
- No validated human dosing exists; all use is experimental and unapproved.
- Animal studies used weight-based oral dosing that reduced fat mass without affecting food intake.
- The key theoretical advantage over DNP is a much wider gap between effective and toxic doses.
Reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
Possible side effects
- Unknown human safety
- Potential overheating (uncoupler class)
- No approved human use
- Requires careful dose control
- Possible energy/fatigue changes
Research
- BAM15 reduces obesity without lowering food intake (2020): Oral BAM15 decreased fat mass and improved insulin sensitivity in obese mice without reducing appetite or muscle.
- BAM15 safety versus DNP (2018): Showed a substantially wider therapeutic window than the classical uncoupler DNP in preclinical models.
Compare BAM15
Research and educational reference only. Not medical advice.